From May 14th to May 15th, 2021, the "First Hetao International Medical Forum" was held in Shenzhen; its theme was "Focusing on the Globalization of Medicine and Building a New Height in the Industry". This conference was jointly planned and prepared by Dr. Du Tao, the sitting president of the FDA Expert Association, and professional conference agencies. The agenda of the conference covered chemical and biological drug innovation, the application of AI technology in drug development, strategies in drug clinical trial, cell and gene therapy, companion diagnostic strategies in new drug development, drug registration regulations, innovation, entrepreneurship and investment, etc. The conference also helped to build up the pharmaceutical innovation industry chain in an all-around and

On May 6, 2021, Evergreen Therapeutics has set its new headquarter in the Radio and Television Financial Center in Futian, Shenzhen. The new site overlooks the top of Lianhua Mountain in the north and is backed by the Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone ("Hetao"). The location will be more beneficial to Evergreen's internationalization and financing activities. In December 2020, the Greater Bay Area Center for Drug Evaluation of National Medical Products Administration was established in Shenzhen's "Hetao". Shenzhen will once again usher in opportunities for the development of biomedical innovation. For this, Dr. Du Tao, Chairman of Evergreen Therapeutics said, “The Greater Bay Area Center of National Medical Products Administration has been e

On March 15, a fast-growing bio-innovative pharmaceutical company, Evergreen Therapeutics, announced the completion of RMB 100 million Series A financing. This round of financing was led by Shenzhen Tiantu Capital, Shenzhen Share Capital, and other investment institutions followed. The funds raised will be used to support Evergreen's new drug research and development, including phase II clinical trial of coronavirus pneumonia injection drug EG-009A and the development of other clinical phases and preclinical projects.  "Evergreen Therapeutical, Inc. received three US FDA clinical approvals in just over a year. Its success is a result of Evergreen’s professional and excellent team, and is also inseparable from the trust and support of investors." Dr. Du Tao, Chairman of Evergr